Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters StreetEvents
$75.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Medivir AB Announces Data from Two Phase III Studies Conducted by Janssen R&D Ireland with Simeprevir in Hepatitis C Subpopulations - HCV/HIV Co-Infected and Genotype 4 Infected Patients


Friday, 18 Oct 2013 09:15am EDT 

Medivir AB announced that the Company has presented preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients. High cure rates were seen in patients co-infected with HCV genotype 1 and HIV-1. The Company believe that simeprevir could provide a new treatment option in this specific patient group. Also positive interim results from patients infected with HCV genotype 4 were seen. 

Company Quote

119.25
-7.25 -5.73%
22 Aug 2014